Annovis Bio Launches Long-Term Parkinson's Study for Buntanetap in 2026

Annovis Bio (NYSE: ANVS), a biotechnology company headquartered in Malvern, Pennsylvania, has announced a significant step forward in its Parkinson's disease research program. The company will initiate an open-label extension study in January 2026 to further evaluate the long-term safety and efficacy of its lead drug candidate, buntanetap. This study is designed to provide continued access to the investigational therapy for participants from prior clinical trials while enabling extended monitoring of safety outcomes, sustained effects on motor and cognitive function, and the collection of biomarker data. The research aims to support further evaluation of buntanetap's potential as a disease-modifying therapy for neurodegenerative disorders, aligning with Annovis Bio's core mission of addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's by developing innovative therapies that target multiple neurotoxic proteins.

The news release was distributed through BioMedWire (“BMW”), a specialized communications platform within the Dynamic Brand Portfolio of IBN that focuses on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. For more detailed information, readers can view the full press release via the provided link. Annovis Bio encourages stakeholders to visit the company’s website and follow its social channels on LinkedIn, X, and YouTube for ongoing updates. The company's newsroom also provides the latest news and updates relating to ANVS, offering investors and the public a centralized source for information. This strategic move into a long-term extension study represents a critical phase in clinical development, where real-world, extended data can provide deeper insights into a therapy's profile beyond initial trial periods.

By launching this open-label extension, Annovis Bio is not only extending care to trial participants but also gathering invaluable long-term data that could substantiate buntanetap's role in potentially slowing or modifying the progression of Parkinson's disease. The collection of biomarker data is particularly noteworthy, as it may offer objective measures of the drug's impact on the underlying disease pathology. For the broader medical and investment community, this development signals continued progress in a challenging therapeutic area, where effective disease-modifying treatments remain a significant unmet need. The involvement of BioMedWire ensures this news reaches a wide audience of investors, journalists, and the general public through its comprehensive distribution network, which includes wire solutions, editorial syndication, and social media channels.